Exocrine pancreatic insufficiency (EPI) refers to the condition
wherein the body is unable to produce sufficient amounts of exocrine
pancreatic enzymes, thus leading to difficulties in digesting food
properly. The condition occurs due to the lack of sufficient enzymes
necessary for fat digestion, amylases for starch digestion, and
proteases for protein digestion. EPI results due to a number of
conditions such as cystic fibrosis, cytomegalovirus infection,
pancreatic cancer, chronic pancreatitis, and HIV/AIDS. In the past
few years, the vast rise in incidence of causative conditions have
driven the global exocrine pancreatic insufficiency (EPI)
therapeutics and diagnostics market.
Enquiry for discount on this report @
https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=2748
According to the report, the global EPI therapeutics and diagnostics
market was valued at US$3,397.5 mn in 2016 and is projected to reach
US$6,414.4 mn by 2025, expanding at a CAGR of 7.2% from 2017 to
2025.
Based on diagnostics, the EPI therapeutics and diagnostics market has
been segmented into blood tests, magnetic resonance imaging (MRI),
endoscopic ultra-sonography (EUS), and Computerized tomography (CT)
scanning. CT scans are conventionally preferred and the most adopted
method used for diagnosing EPI. The segment held the dominant chunk
in the global market in 2016. While many healthcare professionals
continue to use the modality owing to widespread availability and low
cost as compared to other scans, the segment is likely to witness
sluggish growth in the near future owing to the introduction of
advanced and more accurate techniques.
Request for Sample Copy of Report @
https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2748
Diagnostic methods such as magnetic resonance imaging (MRI), which
have been known to be more sensitive when compared to CT scans, are
witnessing increasingly high demand across the globe. The segment of
MRI is thus emerging as the technique of choice for the analysis of
chronic pancreatitis along with CT scans. Hence, the MRI segment is
likely to outpace other segments in terms of CAGR during the forecast
period.
Geographically, the report examines the EPI therapeutics and
diagnostics market across regions such as Asia Pacific, North
America, Europe, Latin America, and Middle East and Africa. Of these,
the market in North America held for the dominant share of the global
market in 2016. The regional market is most likely to remain the
dominant regional market over the forecast period as well, thanks to
the increased cost per prescription for PERT products in the U.S.
Factors such as the massive rise in incidence of exocrine pancreatic
insufficiency and other causative conditions such as diabetes and
cystic fibrosis in the U.S. is expected to remain a key factor
contributing to the strong position of the North America market.
Request a Brochure of the Report @
https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2748
The report estimates that the EPI therapeutics and diagnostics market
in Asia Pacific will outpace other regional markets over the forecast
period owing to the increasing population of geriatrics in countries
such as China, Japan, and Singapore. Moreover, rising incidence of
chronic pancreatitis in India, Malaysia, and China is likely to
support market growth. The EPI therapeutics and diagnostics market in
Latin America is also projected to exhibit a vast rise in growth
opportunities during the forecast period. Factors such as rising
incidence of causative diseases, increased focus of governments on
improving the healthcare infrastructure of emerging economies, and
rising investments by market players are the key factors expected to
fuel the market in the region.
Some of the leading companies operating in the global EPI
therapeutics and diagnostics market are AbbVie, Inc., Allergan plc,
Anthera Pharmaceuticals, Inc., Digestive Care, Inc., Janssen
Pharmaceuticals, Inc., Nordmark Arzneimittel GmbH & Co. KG,
Cilian AG, and AzurRx Biopharma, Inc.
About Us
Transparency Market Research (TMR) is a market intelligence company,
providing global business information reports and services. Our
exclusive blend of quantitative forecasting and trends analysis
provides forward-looking insight for thousands of decision makers.
TMR’s experienced team of analysts, researchers, and consultants,
use proprietary data sources and various tools and techniques to
gather, and analyze information. Our business offerings represent the
latest and the most reliable information indispensable for businesses
to sustain a competitive edge.
Each TMR syndicated research report covers a different sector - such
as pharmaceuticals, chemicals, energy, food & beverages,
semiconductors, med-devices, consumer goods and technology. These
reports provide in-depth analysis and deep segmentation to possible
micro levels. With wider scope and stratified research methodology,
TMR’s syndicated reports strive to provide clients to serve their
overall research requirement.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email:
sales@transparencymarketresearch.com
Website:
https://www.transparencymarketresearch.com
No comments:
Post a Comment